Abstract:Abstract Background and Aims Membranous nephropathy (MN) is considered one of the major conditions causing nephrotic-range proteinuria. Last years brought a huge progress in the field of non-invasive diagnostics, mainly due to the PLA2R antibody use in diagnostics and follow-up of primary MN. However, our understanding of MN is far from complete, especially that PLA2R-antibodies are found only in approximately 60-70% of all cases. Urinary proteomics is a promising tool that can help us to improve diagnostics, monitoring and understanding of MN. Our previous studies (Patent No. WO/2017/212463) suggested that specific urinary proteins can be used in the diagnostics of IgA nephropathy, lupus nephritis and ADPKD. The aim of this study was to evaluate with Mass Spectrometry (MS) patients diagnosed with MN in comparison to healthy controls. Method This study included patients with biopsy-proven MN (25) and healthy controls (7). Urine samples were obtained from a midstream of the second- or third-morning (SPOT) sample. The samples were processed up to 2 h after collection and stored at -80°C for further measurements with MS. The results were related to demographic data, standard laboratory tests and GFR estimated with use of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results The signal intensity of urine protein A, B and C (patent pending and the name of proteins disclosed until the date of ERA-EDTA Congress) was found to be significantly higher (p < 0.05) in MN patients compared to healthy controls (Fig. 1). Mass spectrometry, according to the specific amino-acids fragments of each tested protein, confirmed the differences between tested and control group. Additionally, statistically significant differences exist between patients with different types of glomerulonephritides (comparative MS in progress). Conclusion The signal intensity of urine proteins A, B, C is elevated in MN and according to our study, vary depending on types of nephropathies. This observation might suggests their differential roles in the pathophysiology of MN and its’ possible application as a non-invasive diagnostic and prognostic marker. Further studies are desired to establish the role of these urinary proteins.

Semiconductor materials and detectors for future very high luminosity colliders

The Application of Podocyte Antigen PLA2R and Anti-Pla2r Antibody in the Diagnosis and Treatment of Membranous Nephropathy

Quantitative Detection of Anti-Pla2r Antibodies Targeting Different Epitopes and Its Clinical Application in Primary Membranous Nephropathy.

Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy.

P0489URINARY PROTEOMIC MARKERS OF MEMBRANOUS NEPHROPATHY

Antiphospholipid Antibodies in Patients with Membranous Nephropathy.

Non-diabetic urine glucose in idiopathic membranous nephropathy

A noninvasive method of diagnosing membranous nephropathy using exosomes derived from urine

Immunology of membranous nephropathy: from animal models to humans

Association of Serum Mannose-Binding Lectin, Anti-Phospholipase A2 Receptor Antibody and Renal Outcomes in Idiopathic Membranous Nephropathy and Atypical Membranous Nephropathy: a Single Center Retrospective Cohort Study.

C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy

The Correlation of Anti-Β2-glycoprotein I Antibody with Complement Activation in Patients with Idiopathic Membranous Nephropathy

Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy

Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy

Anti-phospholipase A2 receptor antibodies directly induced podocyte damage <i>in vitro</i>

Detection And Clinical Significance Of Glomerular M-Type Phospholipase A(2) Receptor In Patients With Idiopathic Membranous Nephropathy

Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.

Peer Review #1 of "retrospective Study: Clinicopathological Features and Prognosis of Idiopathic Membranous Nephropathy with Seronegative Anti-Phospholipase A2 Receptor Antibody (V0.2)"

Progress on the M-type Phospholipase A2 Receptor in Idiopathic Membranous Nephropathy

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody.

Detection of Phospholipase A2 Receptor Related Membranous Nephropathy in Membranous Nephropathy Patient